Funding boosts development plans for virus busters
One of Cheshire’s leading scientific and research companies, Arcis-Altos Group, has received a £1m funding boost after agreeing a deal with Calculus Capital, one of the UK’s leading Enterprise Investment Scheme (EIS) funds.
Arcis-Altos Group, based at the Sci-Tech Daresbury innovation campus, has developed Noroclear, a world-leading disinfection product scientifically proven to combat norovirus within one minute.
The new funding will be used to accelerate development activities focusing on DNA extraction from cells and the subsequent protection of the DNA to allow diagnostic devices to provide a more accurate analysis. This opportunity is expected to further revolutionise the molecular diagnostic sector, an area which is increasingly relied on in both medical and forensic sciences.
Peter Whitehurst, CEO at Arcis, said: “This is very welcome news at a key time for Arcis-Altos.We are delighted that Calculus Capital continues to strongly back Arcis-Altos and its management team.”
About Calculus Capital Ltd, founded in 1999, specialises in creating and managing private equity funds for individuals. The firm’s range of EIS and Venture Capital Trust (VCT) funds invest in UK unquoted companies.
This was posted in Bdaily's Members' News section by Simon Malia .